REFERENCES
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.
Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 1998 Nov;37(45):15908-17.
AVERT, International HIV and AIDS charity. HIV & AIDS in Thailand [Online].
Available: http://www.avert.org/thailand-aids-hiv.htm#ref30#ref30 [2010, May 10].
Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84.
Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue- resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Antivir Ther. 2000 Mar;5(1):7-14.
Beck IA, Crowell C, Kittoe R, Bredell H, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):418-27.
Beck IA, Mahalanabis M, Pepper G, Wright A, et al. Rapid and Sensitive Oligonucleotide Ligation Assay for detection of mutations in Human Immunodeficiency Virus Type 1 associated with high-level resistance to Protease Inhibitors. J Clin Microbiol. 2002 Apr;40(4):1413-9.
Becker SL, Dezii CM, Burtcel B, Kawabata H, Hodder S. Young HIV-infected adults are at greater risk for medication nonadherence. MedGenMed. 2002 Jul;
30;4(3):21.
Bergroth T, Sönnerborg A, Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods. 2005 Jul;127(1):100-7.
Birk M, Svedhem V, and Sonnerborg A. Kinetics of HIV-1 RNA and resistance- associated mutations after cessation of antiretroviral combination therapy.
AIDS. 2001 Jul;15(11):1359-68.
Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (¡) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Antimicrob Agents Chemother. 1993 Oct;37(10):2231-4.
Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1993 Apr;67(4):2412-20.
Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis. 1997 Jul-Sep;3(3):253-9.
Centers for Disease Control & Prevention (CDC). Divisions of HIV/AIDS Prevention (2003). HIV and Its Transmission [Online]. Available: http://web.
archive.org/web/20050204141148/http://www.cdc.gov/HIV/pubs/facts/transm ission [2009, May 23].
Central Intelligence Agency (CIA). The World Factbook. Country Comparison : HIV/AIDS - adult prevalence rate [Online]. Available:
https://www.cia.gov/library/publications/the-world-factbook/rankorder/2155 rank.html [2010, Jan 04].
Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998 May 29;93(5):681-4.
Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997 Apr 18;89(2):263-73.
Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem. 1995 Sep;270(37):21433-6.
Chun TW, Davey Jr. TR, Ostrowski M, Shawn J, et al. Relationship between pre- existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000 Jul;
6(7): 757-61.
Clavel F, Hance AJ. HIV Drug Resistance. N Engl J Med. 2004 Mar;350:1023-35.
Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
AIDS. 2000 Jan 28;14(2):F9-15.
Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Sciences. 1995; 267(5197): 483-9.
Cohen J. Thailand’s do-it-yourself therapy. Science. 2003 Sep;301(5640): 1662.
Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374(6522):569-71.
Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol. 2010 Aug;13(4):524-9.
Davies E. Update on antiretroviral therapy. The Pharmaceutical Journal 2000; 264:
96-7.
Deeks SG, Wrin T, Liegler T, Hoh R, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001 Feb; 344(7): 472-80.
DeGruttola V, Dix L, D’Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther.
2000 Mar;5(1):41-8.
Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al.
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA. 2000 Jan;283(2):205-11.
Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM.
Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol. 1998 Feb;36(2):569-72.
Ellis GM, Mahalanabis M, Beck IA, Pepper G, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004 Aug;42(8):3670-4.
Esnouf RM, Ren J, Hopkins AL, et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci U S A. 1997 Apr;94(8):3984-9.
Frenkel L. M, Wagner II E. L, Atwood M. S, Cummins J. T, and Dewhurst. Specific, sensitive, and rapid assay for Human Immunodeficiency Virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol. 1995 Feb;33(2):342-7.
Gazzard B, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006 Nov;
7(8):487-503.
Gelderblom HR. "Fine structure of HIV and SIV" (1997). In Los Alamos National Laboratory (ed.) (PDF). HIV Sequence Compendium. Los Alamos, New Mexico: Los Alamos National Laboratory. pp. 31–44 [Online]. Available:
http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/1997/partIII/
Gelderblom.pdf [2010, Jan 10].
Gilbert PB, McKeague IW, Eisen G, Mullins C, Gueye NA, Mboup S, et al.
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med. 2003 Feb 28;22(4):573-93.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al.
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV- 1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011 Jul;11(7):507-15.
Halvas EK, Aldrovandi GM, Balfe P, Beck IA, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol. 2006 Jul;44(7):2612-4.
Hammer MS, Saag SM, Schechter M, Montaner J, et al. Treatment for adult HIV infection 2006 Recommendations of the International AIDS society-USA panel. JAMA. 2006 Aug; 296(7): 827-43.
Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA.
2000 Jan;283(2):229-34.
Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006 Oct 24;20(16):W13-23.
Hermankova M, Ray CS, Ruff C, Powell-Davis M, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 Copies/mL receiving combination therapy. JAMA. 2001 July; 286(2): 196-207.
Hirsch MS, Brun-Vezinet F, D’Aquila TR, Hammer MS, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. JAMA. 2000 May; 283(18): 2417-26.
Hong L, Zhang XC, Hartsuck JA, Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 2000 Oct;9(10):1898-904.
Hsiou Y, Ding J, Das K, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol. 2001 Jun;309(2):437-45.
Izopet J, Massip P, Souyris C, Sandres K,et al. Shift in HIV resistance genotype after treatment interuption and short-term antiviral effect following a new salvage regimen. AIDS. 2000 Oct;14(15): 2247-55.
Jallow S, Kaye S, Schutten M, Brandin E, et al. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J Clin Microbiol. 2007 May;45(5):1565-71.
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard H. F, et al. Update of the Drug Resistance Mutations in HIV-1: December 2008. Top HIV Med. 2008 Dec;
16(5): 138-145.
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al.
Update of the Drug Resistance Mutation in HIV-1: Spring 2008. Top HIV Med; 2008 Apr-May;16(1): 62-8.
Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A. 1994 Jun;91(12):5597-601.
Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003 May;348(22):2228-38.
Landegren U, Kaiser R, Sanders L and Hood L. A ligase-mediated gene detection technique. Science. 1988 August; 241(4869): 1077-80.
Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high- level resistance to zidovudine (AZT). Science. 1989 Dec;246(4934):1155-8.
Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999 Dec;282(23):2220-6.
Lehman IR. DNA ligase: structure, mechanism, and function. Science. 1974 Nov 29;186(4166):790-7.
Levy JA. HIV pathogenesis and long-term survival. AIDS. 1993 Nov;7(11):1401-10.
Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir, Ther. 2000; 5:33-40.
Los Alamos National Laboratory. HIV Sequence Compendium 2008 : Introduction [Online]. Available: http://www.hiv.lanl.gov/content/sequence/HIV/COM PENDIUM/2008/frontmatter.pdf [2009, Mar 31].
Mansky LM. Retrovirus mutation rates and their role in genetic variation. J Gen Virol.
1998 Jun;79(Pt 6): 1337-45.
McGovern SL, Caselli E, Grigorieff N, Shoichet BK. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
J Med Chem. 2002 Apr 11;45(8):1712-22.
Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, et al. Emergence of minor population of Human Immunodeficiency Virus type 1 carrying the M184V and L90M mutation in subjects undergoing structured treatment interruptions.
J Infect Dis. 2003 Nov; 188(10): 1433-43.
Metzner KJ, Rauch P, Walter H, Boesecke C, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005 Nov 4;19(16) :1819-25.
Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell. 1999 Jul;4(1):35-43.
Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996 Jul;2(7):760-6.
Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004 Jan 20;170(2):229-38.
Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002 Mar 8;16(4):597-603.
National AIDS Prevention and Alleviation Committee. UNGASS Country Progress Report Thailand : Reporting Period January 2008- December 2009 [Online].
Available: http://aidsdatahub.org/dmdocuments/thailand_2010_country_
progress_ report _en.pdf [2010, Jun 10].
National Institute of Allergy and Infectious Diseases (NIAID). Crystal Structure of Key HIV Protein Reveals New Prevention, Treatment Targets [Online].
Available: http://www.niaid.nih.gov/news/newsreleases/1998/Pages/hivprotein .aspx [2010, June 10].
Nissley DV, Halvas EK, Hoppman LN, Garfinkel JD, et al. Sensitive phenotype detection of minor drug resistant HIV-1 reverse transcriptase variants. J Clin Microbiol. 2005 Nov; 43(11): 5696-5704.
O’Meara D, Wilbe K, Leitner T, Hejdeman B, et al. Monitoring resistance to Human Immunodeficiency Virus type 1 protease inhibitor by pyrosequencing. J Clin Microbiol. 2001 Feb; 39(2): 464-73.
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar;
338(13): 853-60.
Palmer S, Boltz V, Maldarelli F, Kearney E, et al. Selection and persistence of non- nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping nonnucleoside therapy. AIDS. 2006 Mar; 20(5): 701-10.
Palmer S, Kearney M, Maldarelli F, Halvas K. E, et al. Multiple, linked Human Immunodeficiency Virus type 1 drug resistance mutations in treatment- experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005 Jan; 43(1): 406-13.
Picard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
J Infect Dis. 2001 Sep; 184(6):781-4.
Piatak M, Jr., Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749-54.
Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009 Aug;15: 871-872.
Podzamczer D, Fumero D. The role of nevirapine in the treatment of HIV-1 disease.
Expert opin Pharmacother. 2001 Dec; 2(12): 2065-78.
Prabu-Jeyabalan M, King N, Nalivaika E, Scott W, Schiffer C. Drug resistance and substrate recognition in HIV-1 protease. Antiviral Ther. 2002;7:Suppl 1:S36.
abstract.
Praparattanapan J, Tragoolpua Y, Wongtrakul J, et al. Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit. Asian Biomedicine. 2011 Apr;5(2):249-55.
Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol. 2002 Jun;83(Pt 6):1253-65.
Ren J, Nichols C, Bird L, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol. 2001 Sep;312(4):795-805.
Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660-6.
Ridky TW, Kikonyogo A, Leis J, et al. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Biochemistry. 1998 Sep;37(39):13835-45.
Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998 Feb;72(2):986-93.
Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet. 2008 Nov 29;372(9653):1857-8.
Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al.
HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6.
Sarafianos SG, Das K, Clark AD Jr, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A. 1999 Aug;96(18):10027-32.
Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411-9.
Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):243-8.
Shackelford W, Deng S, Murayama K, and Wang J. A new technology for mutation detection. Ann N Y Acad Sci. 2004 Jun; 1022: 257-62.
Shafer RW, Winters MA, Jellinger RM, Merigan TC. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis. 1996 Aug;174(2):448-9.
Smith JA, Daniel R. Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses. ACS Chem Biol. 2006 May 23;1(4):217- 26.
Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug- selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997 Feb;41(2):284-291.
Stuyver L, Wyseur A, Rombout A, Louwagie J, et al. Line probe assay for rapid detection of drug-selected mutations in the Human Immunodeficiency Virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997 Feb;
41(2): 284-91.
Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, et al.
Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine. 2010 Aug; 4(4): 515-28.
Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type-1 infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine and nevirapine fails. Clin Infect Dis. 2007 Feb; 44(3):
447-52.
Sungkanuparph S, Oyomopito R, Sirivichayakul S, et al. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis. 2011 Apr 15;52(8):1053-7.
Sutthent R, Arworn D, Kaoriangudom S, Chokphaibulkit K, Chaisilwatana P, Wirachsilp P, et al. HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program. J Clin Virol. 2005 Dec;34(4):272- 6.
Takehisa J, Kraus MH, Ayouba A, Bailes E, Van Heuverswyn F, Decker JM, et al.
Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol. 2009 Feb;83(4):1635-48.
Thailand MoPH. HIV/AIDS analytical situation in Thailand 2011, HIV/AIDS epidemic in Thailand reported from Bureau of Epidemiology, MOPH [Online]. Available:http://www.aidsthai.org [2011, Oct 10].
The Lancet. A (prime) boost for HIV vaccine research? Lancet. 2009 Oct 3;374(9696):1119.
Timson DJ, Singleton MR, Wigley DB.DNA ligases in the repair and replication of DNA. Mutat Res. 2000 Aug;460(3-4):301-18.
Tobe V, Taylor S, Nickerson AD. Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay. Nucleic Acid. 1996 Oct; 24: 3728-32.
Tsongalis G, Gleeson T, Rodina M, Anamani D, et al. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clnical isolates. J Clin Virol. 2005 Dec; 34(4): 268-71.
Turner D, Brenner B, and Wainberg A. M. Minireviews: Multiple effects of the M184V resistance mutation in the reverse transcriptase of Human Immunodeficiency Virus type 1. Clin Diagn Lab Immunol. 2003 Nov; 10(6) : 979-81.
UNAIDS. UNAIDS report on the global AIDS epidemic 2010 [Online]. Available:
http://www. unaids.org/globalreport/documents/20101123_GlobalReport_full _en.pdf [2011, Apr 24].
Utaipat U, Duerr A, Rudolph, DL, Yang C, et al. Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. AIDS Res Hum Retroviruses. 2002;18(1):1-11.
Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature. 2006 Nov;444(7116):164.
Vilahermosa ML, Beck I, Perez-Alvarez L, Conteras G, et al. Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J Hum Virol. 2001 Sep- Oct; 4(5): 238-48.
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998 Jun;279(24):1977-83.
Wallis CL, Mahomed I, Morris L, Chidarikire T, et al. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May;125(2):99-109.
Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905.
Weiss RA. How does HIV cause AIDS? Science. 1993 May; 260 (5112): 1273–9.
Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998 Jun;280 (5371):1884–8.
Yerly S, Kaiser L,Race E, et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. The Lancet. 1999 Aug;354(9180):729.
Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol Lett. 2005 Mar 15;97(2):225-34.
